Drugmakers are working as quickly as possible to develop a vaccine to combat the rapidly spreading coronavirus that has infected more than 156,400 people worldwide.
Behind the scenes, scientists and medical experts are concerned that rushing a vaccine could end up worsening the infection in some patients rather than preventing it.
Studies have suggested that coronavirus vaccines carry the risk of what is known as vaccine enhancement, where instead of protecting against infection, the vaccine can actually make the disease worse when a vaccinated person is infected with the virus.
The mechanism that causes that risk is not fully understood and is one of the stumbling blocks that has prevented the successful development of a coronavirus vaccine.
Normally, researchers would take months to test for the possibility of vaccine enhancement in animals. Given the urgency to stem the spread of the new coronavirus, some drugmakers are moving straight into small-scale human tests, without waiting for the completion of such animal tests.
“I understand the importance of accelerating timelines for vaccines in general, but from everything I know, this is not the vaccine to be doing it with,” said Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston, Texas.
Hotez worked on development of a vaccine for SARS, the coronavirus behind a major 2003 outbreak, and found that some vaccinated animals developed more severe disease compared with unvaccinated animals when they were exposed to the virus.
“There is a risk of immune enhancement,” Hotez said. “The way you reduce that risk is first you show it does not occur in laboratory animals.”
Hotez testified earlier this month before the US House of Representatives Committee on Science, Space and Technology about the need for sustained funding for vaccine research.
There remains no vaccine for any of the new coronaviruses that have caused outbreaks in the past 20 years.
At least for now, the world’s experts have concluded that accelerated testing is a risk worth taking.
At a specially convened WHO meeting in the middle of last month, designed to coordinate a global response to the new coronavirus, scientists representing government-funded research organizations and drugmakers around the world agreed that the threat was so great that vaccine developers should move quickly into human trials, before animal testing is completed, four people who attended the meeting said.
“You want to have a vaccine as quickly as possible,” said former WHO assistant director-general Marie-Paule Kieny, who co-chaired the meeting. “You have to balance this with the risk that you impose on a very small number of people, and do all you can do to mitigate this risk as much as possible.”
The conclusion of that meeting, which was not open to media, has not been officially publicized by the WHO.
It does not reflect any official position adopted by the WHO, a UN body whose job it is to help shape global health policy.
Regulatory oversight of drugmakers and medical research is in the hands of national regulators. The most powerful of those, the US Food and Drug Administration (FDA), has signaled that it is in agreement with the consensus and would not stand in the way of accelerated testing schedules.
“When responding to an urgent public health situation such as novel coronavirus, we intend to exercise regulatory flexibility and consider all data relevant to a certain vaccine platform,” FDA spokeswoman Stephanie Caccomo said in a statement.
The agency had no comment specifically on animal testing for vaccine enhancement.
Coronavirus vaccine developers are still required to conduct routine animal testing to make sure the vaccine itself is not toxic and is likely to help the immune system respond to the virus.
About 20 coronavirus vaccine candidates are being developed by research institutes and drugmakers including Johnson & Johnson (J&J) in the US and France’s Sanofi SA.
The US government has earmarked more than US$3 billion for coronavirus treatments and vaccines.
Biotechnology company Moderna, which is working with the US National Institutes of Health (NIH), is the closest to human testing, announcing plans to start a trial with 45 people in Seattle this month.
Testing for the specific risk of vaccine enhancement in animals is to proceed simultaneously with human trials, which should establish whether it is safe to expose larger numbers of people to the vaccine, the NIH told reporters.
Moderna did not respond to requests for comment.
The plan is consistent with the WHO consensus and FDA requirements, said Emily Erbelding, director of the Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases, part of the NIH.
The trial is expected to take 14 months, an NHI spokeswoman said.
Gregory Poland, a virologist and vaccine researcher with the Mayo Clinic in Rochester, Minnesota, expressed doubts about that approach.
“This is important, but it has to be done in a way that reassures scientists and the public that these [vaccines] are not only efficacious, but safe,” he said.
Hotez said he was surprised human trials were going ahead.
“If there is immune enhancement in laboratory animals vaccinated with the Moderna vaccine, that’s a showstopper,” he said.
US immunotherapy company Inovio Pharmaceuticals, which is developing a coronavirus vaccine in collaboration with a Chinese company, also expects to start human clinical trials in 30 US volunteers next month rather than wait for animal studies on vaccine enhancement.
“The community as a whole weighed that and said we don’t want to delay the clinical process. We’ve been encouraged to go as rapidly as possible into Phase 1 studies,” Inovio chief executive Joseph Kim said.
Inovio plans to start human safety trials shortly thereafter in China and South Korea — two countries that have been hit hard by the virus.
Kim said he expects to have an answer to the question of vaccine enhancement at some point this year.
The Moderna/NIH trial is enrolling patients at the Kaiser Permanente Washington Health Research Institute in Seattle. The choice of location, made several weeks ago, could prove to be problematic.
To reduce the risk to volunteers, scientists at the WHO meeting recommended that drugmakers restrict early clinical trials to small groups of healthy people and conduct them in places where the virus is not spreading, said Kieny, who now works at French research institute Inserm.
That lowers the chances that people who get the vaccine could encounter the virus and trigger a more severe reaction.
Since the location was chosen, the Seattle metro area has emerged as the epicenter of infections in the US.
Washington state has reported 550 coronavirus infections and 50 deaths, out of a more than 2,952 infections and 60 deaths in the country, according the Johns Hopkins University Center for Systems Science and Engineering COVID-10 tracker yesterday afternoon.
Nevertheless, Moderna and the NIH plan to go ahead.
“We think there is no reason to have to change the site. If you change it, there might be community transmission in another site over the next couple of weeks,” Erbelding said. “Any risk of that to participants is very small. It would be manageable as the trial progresses. People are being observed very, very carefully.”
EARLY WARNING SIGNS
Tragic lessons from other vaccines and prior work on coronaviruses have raised some warning flags for developers.
The best-known example occurred in a US trial in the 1960s of a vaccine created by the NIH and licensed to Pfizer to fight respiratory syncytial virus (RSV), which causes pneumonia in infants.
The vast majority of babies who received the vaccine developed more severe disease, and two toddlers died.
A more recent example occurred in the Philippines, where some 800,000 children were vaccinated with Sanofi’s dengue vaccine, Dengvaxia.
Only afterward did the company learn that it could increase the risk of more severe disease in a small percentage of individuals.
Research, including that conducted by Hotez, has shown that coronaviruses in particular have the potential to produce this kind of response.
However, testing for the risk of vaccine enhancement is time-consuming, because it requires scientists to breed mice that are genetically altered to respond to the virus like humans.
Work on these and other animal models is just getting under way in several laboratories around the world.
Moderna, Inovio and several other vaccine developers are not waiting for that process to be completed and are planning to launch human trials in record time for a virus that was only discovered in December last year.
Moderna and Inovio say their vaccines are likely to have a lower risk of vaccine enhancement, because they are made using newer technology that focuses on specific genes on the outer “spike” portion of the virus.
Coronavirus vaccines that caused vaccine enhancement were typically made using an inactivated version of the entire virus.
Neither company has produced a licensed vaccine to date.
J&J said it is developing animal models to test for vaccine enhancement and hopes to have a vaccine candidate ready for human trials in October.
A Sanofi spokeswoman said the company would examine this risk before testing the vaccine in clinical trials.
“People know how traumatic the RSV experience was,” said Johan Van Hoof, global head of Janssen Vaccines, J&J’s vaccine unit. “When you see signals in animals like this, we should not ignore them.”
Additional reporting by Michael Erman and AP
There are few coincidences in the world of foreign diplomacy. Two days after a Japanese government donation of AstraZeneca COVID-19 vaccines arrived in Taiwan on Friday last week, a US delegation led by US senators Tammy Duckworth, Dan Sullivan and Chris Coons touched down at Taipei International Airport (Songshan airport) in a US military transport aircraft, which flew in from Osan Air Base in South Korea. The cross-party delegation of US senators announced that Washington would donate 750,000 COVID-19 vaccine doses to Taiwan in the first wave of the US Foreign Vaccine Sharing Program. Japan and the US’ vaccine donations are
US President Joe Biden has directed an intensive study of the origin of the coronavirus pandemic. In the process of that review, the intelligence community also should look at the larger question: Did China take advantage of the pandemic’s ravaging spread as a limited form of biological warfare against its perceived adversaries? The notion, as unthinkable as it might seem, is no longer as implausible or paranoid as it was earlier portrayed. Mounting questions and evidence have cast doubt on the likelihood that the deadly pathogen sprang naturally from an animal to human. Governments outside China are focusing attention on
On Tuesday, a total of 28 People’s Liberation Army (PLA) aircraft intruded into southwestern, southern and eastern areas of Taiwan’s air defense identification zone (ADIZ), a record number since the Ministry of National Defense began publishing PLA aircraft movements last year. Taking off from air bases on China’s east coast, 10 Shenyang J-16 multirole strike fighters, six Shenyang J-11 fighter jets and two Shaanxi KJ-500 airborne early warning and control aircraft flew on a course adjacent to the Taiwan-controlled Pratas Islands (Dongsha Islands, 東沙群島) before turning back. In a separate formation, an assortment of aircraft, including heavy bombers, more J-16s, electronic warfare
NATO leaders in a communique on Monday described China as a threat to the “rules-based international order and to areas relevant to alliance security,” marking a major change of focus for the organization. They said that China “is rapidly expanding its nuclear arsenal,” is “opaque” about its military modernization and is “cooperating militarily with Russia.” Following the NATO meeting in Brussels, US President Joe Biden assured the alliance that the US would honor its NATO commitments, and said that China and Russia were attempting to drive a wedge between the Washington and European allies. “I want all Europe to know that the United